Ross began worked at the MRC Genome Damage and Stability Centre (University of Sussex, UK) from 2002-2005, before moving to pursue a PhD in DNA double-strand break repair biology with Professor Sir Stephen Jackson at the Gurdon Institute (University of Cambridge, UK). There his research used human and fission yeast cellular models to investigates how DNA damage signalling and repair proteins assemble at sites of DNA damage, and the role played by chromatin and histone modifications. Ross furthered these investigations as a Sir Henry Wellcome Postdoctoral Fellow in 2010, working at Cancer Research UK’s Clare Hall Laboratories with Prof. Simon Boulton. There, his research helped define a 53BP1-dependent DNA repair pathway that mediates adaptive immune system diversification in mammals, yet that promotes genome mutagenesis and chromosomal rearrangement in BRCA1-mutant breast and ovarian cancers. In 2013, Ross established his team at the Wellcome Centre for Human Genetics at the University of Oxford, investigating DNA damage signalling and repair biology with a focus on advancing the understanding of genomic instability-driven human diseases including cancer. Their work has also pursued an understanding of the tumour suppressive activities of the BRCA1, ATM and p53 genome-maintenance proteins, and the contribution of DNA repair to haematopoietic health, longevity, and adaptive immunity. In 2020, Ross and his team moved to the Medical Research Council (MRC) Molecular Haematology Unit at the Weatherall Institute of Molecular Medicine (University of Oxford) where he was promoted to Professor of Genome Maintenance Biology in 2022. He currently holds a Cancer Research UK Senior Fellowship, is a Medical Research Council (UKRI) Programme Leader, was a recipient of a 2019 Lister Prize, and is an elected member of the EMBO Young Investigator Programme. His group receives funding from Cancer Research UK, MRC/UKRI, the Lister Institute, and Breast Cancer Now.